[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336012-105":59,"doc-detail-336012-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","microrna5613p-indirectly-regulates-the-pdl1-expression-by-targeting-zeb1-hif1a-and-myc-genes-in-breast-cancer","MicroRNA‑561‑3p Indirectly Regulates the PD‑L1 Expression by Targeting ZEB1, HIF1A, and MYC Genes in Breast Cancer","","Breast cancer is a major cause of cancer-related death among women, and microRNAs are key regulators of tumor initiation and development. This study examines how microRNA‑561‑3p (miR‑561‑3p) inhibits ZEB1, HIF1A, and MYC expression and thereby affects PD‑L1 overexpression and key cellular processes including proliferation, apoptosis, and the cell cycle in breast cancer cell lines. Using qRT‑PCR, luciferase reporter assays, MTT, Annexin‑PI staining, cell cycle experiments, and flow cytometry, miR‑561‑3p was shown to downregulate oncogenic targets, suppress PD‑L1 at mRNA and protein levels, reduce proliferation, induce apoptosis, and cause cell cycle arrest. The work supports miR‑561‑3p as a potential biomarker and therapeutic target for cancer immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microrna5613p-indirectly-regulates-the-pdl1-expression-by-targeting-zeb1-hif1a-and-myc-genes-in-breast-cancer/336012/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microrna5613p-indirectly-regulates-the-pdl1-expression-by-targeting-zeb1-hif1a-and-myc-genes-in-breast-cancer/336012.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on miR‑561‑3p?","Question",{"text":112,"@type":113},"To determine the inhibitory effect of miR‑561‑3p on ZEB1, HIF1A, and MYC expression and how this influences PD‑L1 overexpression and related cellular processes in breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which experimental approaches were used to assess miR‑561‑3p effects?",{"text":117,"@type":113},"ZEB1, HIF1A, and MYC and miR‑561‑3p levels were measured by qRT‑PCR, while luciferase assays, MTT, Annexin‑PI staining, cell cycle experiments, and flow cytometry evaluated targeting and functional outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the luciferase assay show regarding miR‑561‑3p?",{"text":121,"@type":113},"The luciferase assay indicated that miR‑561‑3p significantly targets the 3′‑UTRs of ZEB1, HIF1A, and MYC genes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336012,1790016144,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMicroRNA‑561‑3p indirectly regulates the PD‑L1 expression by targeting ZEB1, HIF1A, and MYC genes in breast cancer  \nAtenaYousefi1, Fattah Sotoodehnejadnematalahi1, Nahid Nafissi2, Sirous Zeinali3 & Masoumeh Azizi3*  \nGlobally, breast cancer is the second most common cause of cancer‑related deaths among women. In breast cancer, microRNAs (miRNAs) are essential for both the initiation and development of tumors. It has been suggested that the tumor suppressor microRNA‑561‑3p (miR‑561‑3p) is crucial in arresting the growth of cancer cells. Further research is necessary to fully understand the role and molecular mechanism of miR‑561 in human BC. The aim of this study was to investigate the inhibitory effect of miR‑561‑3p on ZEB1, HIF1A, and MYC expression as oncogenes that have the most impact on PD‑L1 overexpression and cellular processes such as proliferation, apoptosis, and cell cycle in breast cancer (BC) cell lines. The expression of ZEB1, HIF1A, and MYC genes and miR‑561‑3p were measured in BC clinical samples and cell lines via qRT‑PCR. The luciferase assay, MTT, Annexin‑PI staining, and cell cycle experiments were used to assess the effect of miR‑561‑3p on candidate gene expression, proliferation, apoptosis, and cell cycle progression. Flow cytometry was used to investigate the effects of miR‑561 on PD‑L1 suppression in the BC cell line. The luciferase assay showed that miRNA‑ 561‑3ptargets the 3′‑UTRs of ZEB1, HIF1A and MYC genes significantly. In BC tissues, the qRT‑PCR results demonstrated that miR‑561‑3p expression was downregulated and the expression of ZEB1, HIF1A and MYC genes was up‑regulated. It was shown that overexpression of miR‑561‑3p decreased PD‑L1 expression and BC cell proliferation, and induced apoptosis and cell cycle arrest through downregulation of candidate oncogenes. Furthermore, inhibition of candidate genes by miR‑561‑3p reduced PD‑L1 at both mRNA and protein levels. Our research investigated the impact of miR‑561‑3pon the expression of ZEB1, HIF1A and MYC in breast cancer cells for the first time. Our findings may help clarify the role of miR‑561‑3p in PD‑L1 regulation and point to this miR as a potential biomarker and novel therapeutic target for cancer immunotherapy.  \nKeywords miRNA-561-3p, ZEB1, HIF1A, MYC, Breast cancer  \nAbbreviations  \nHIF1A Hypoxia-inducible factor 1-alpha ZEB1 Zinc finger E-box-binding homeobox 1 PD-L1 Programmed cell death ligand 1 PD-1 Programmed cell death protein 1  \nBC Breast cancer  \nmiR-561 MicroRNA-561-3p  \nEMT Epithelial-mesenchymal transition  \nCSC Cancer stem cell  \nPI Propidium iodide  \n1Department of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran. 2Breast Surgery Department, Iran University of Medical Sciences, Tehran, Iran. 3Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, 69th Pasteur Street, Kargar Avenue,  \nTehran, Iran.*[email: mazizi528@gmail.com](email: mazizi528@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nBreast cancer (BC) has been a significant threat to women’s health. The incidence of BC is different in various ethnicities, and it is estimated that the number of BC cases will reach more than three million by 2050 worldwide. The mortality rate of BC in developed countries due to novel diagnostic and advanced medical treatment technology would be decreased1,2. Currently, BC treatments include surgery, radiotherapy, chemotherapy, and targeted therapy. Due to the heterogeneity of tumor tissue, the cancer stem cells (CSC) inside the tumor can self-renew and differentiate. Therefore, chemotherapy can lead to chemoresistance and the progression of the disease. It was shown that invasion and subsequent metastasis are the leading causes of death in about half of the BC patients3,4.  \nProgrammed death ligand 1(PD-L1) is expressed by the CD274 ","cbCailZX4w4r6omN","https://ap.wps.com/l/cbCailZX4w4r6omN","pdf",4498872,14,"English","# Background\n## Breast cancer overview and treatment challenges\n## PD‑1/PD‑L1 immune checkpoint axis\n## Regulation of PD‑L1 and links to EMT and CSC phenotype\n## EMT regulators and signaling pathways\n## Role of ZEB1 and connection to miRNA networks\n# Methods and assays\n## Gene and miRNA expression measurement\n## Functional assays for proliferation, apoptosis, and cell cycle\n## Reporter and targeting validation\n## Flow cytometry for PD‑L1 suppression","[{\"question\":\"What is the main goal of the study on miR‑561‑3p?\",\"answer\":\"To determine the inhibitory effect of miR‑561‑3p on ZEB1, HIF1A, and MYC expression and how this influences PD‑L1 overexpression and related cellular processes in breast cancer.\"},{\"question\":\"Which experimental approaches were used to assess miR‑561‑3p effects?\",\"answer\":\"ZEB1, HIF1A, and MYC and miR‑561‑3p levels were measured by qRT‑PCR, while luciferase assays, MTT, Annexin‑PI staining, cell cycle experiments, and flow cytometry evaluated targeting and functional outcomes.\"},{\"question\":\"What did the luciferase assay show regarding miR‑561‑3p?\",\"answer\":\"The luciferase assay indicated that miR‑561‑3p significantly targets the 3′‑UTRs of ZEB1, HIF1A, and MYC genes.\"}]","MicroRNA‑561‑3p Indirectly Regulates the PD‑L1 Expression by Targeting ZEB1, HIF1A, and MYC Genes in Breast Cancer | PDF",1790013165,35]